Vanderbilt Center For Neuroscience Drug Discovery

Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications. Read More

Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia. Read More

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS). Read More

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported. Read More

Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan. Read More

P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health. Read More

Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology. Read More

Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit. Read More

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read More

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice. Read More

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation. Read More

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read More

Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit. Read More

A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder. Read More

Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma. Read More

Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans. Read More

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness. Read More

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way. Read More

Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease. Read More

Vanderbilt University’s Craig Lindsley, Ph.D., is the 2013 recipient of the Philip S. Portoghese Lectureship, awarded jointly by the Journal of Medicinal Chemistry and the American Chemical Society (ACS) Division of Medicinal Chemistry. Read More